Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Defining remission in childhood-onset lupus: PReS-endorsed consensus definitions by an international task force

Clinical Immunology(2024)10.1016/j.clim.2024.110214Source: DataRank Database

Defining remission in childhood-onset lupus: PReS-endorsed consensus definitions by an international task force is a research paper published in Clinical Immunology (2024). On theSindex it has a DataRank of 0. It has been cited 20 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access20 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 6.70)OA: hybridTopics (61)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (28)

Amita Aggarwal ORCID,Jenny Ainsworth ORCID,Eslam Al‐Abadi ORCID,Tadej Avčin ORCID,Lynette Bortey

Live enrichment

PubMed:38604255 PMC:PMC12345350 OpenAlex:https://openalex.org/W4394600484

Versus Arthritis

Grant: 20621

Intramural NIH HHS

Grant: ZIA AR041214

Intramural NIH HHS

Grant: Z99 AR999999

Wellcome Trust

Grant: 204822

Institutional Strategic Support Fund

Wellcome Trust

FWCI

6.70

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

hybridLicense: cc-by

journalhttps://doi.org/10.1016/j.clim.2024.110214

publisherhttps://doi.org/10.1016/j.clim.2024.110214

publisherhttps://api.elsevier.com/content/article/PII:S1521661624001050?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1521661624001050?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38604255

Fields of Study

Systemic Lupus Erythematosus ResearchAutoimmune and Inflammatory Disorders Researchinterferon and immune responses03 medical and health sciences0302 clinical medicineChildHumansAdvisory CommitteesAge of OnsetConsensusDelphi TechniqueImmunosuppressive AgentsLupus Erythematosus, SystemicRemission Induction

MeSH Terms

ChildDelphi TechniqueHumansImmunosuppressive AgentsLupus Erythematosus, SystemicRemission InductionAge of OnsetAdvisory CommitteesConsensus

Keywords

MedicinePrednisoloneSystemic lupus erythematosusObservational studyTask forcePediatricsClinical trialPhysical therapyInternal medicineDiseaseRemissionTreat-to-targetChildhood-onset SleCsleT2tRegulatory T Cell Development and FunctionConsensusDelphi TechniqueFOS: Political scienceAdvisory CommitteesImmunologyArticleRheumatologyHealth SciencesImmune ToleranceHumansLupus Erythematosus, SystemicAge of OnsetChildPolitical scienceImmunology and MicrobiologyFOS: Clinical medicinePublic administrationRemission InductionLife SciencesSystemic Lupus Erythematosus and Antiphospholipid SyndromeImmunosuppressive AgentsNatural Killer Cells in Immunity

Sustainable Development Goals

SDG 3: 3. Good health